First Daily Psoriasis Pill Approved, No Needles Needed

Millions of people living with psoriasis just got a game-changing new option that doesn't involve needles.

Johnson & Johnson received U.S. approval this week for Icotyde, the first daily pill that delivers the same powerful results as injectable psoriasis medications. The drug works for patients over age 12 with moderate to severe plaque psoriasis, offering relief without the anxiety or inconvenience of regular injections.

The breakthrough addresses a major gap in treatment. Right now, patients typically start with creams and lotions, then move to injectable drugs when those stop working. But many people skip treatment altogether because shots feel too difficult, expensive, or scary to manage long-term.

Icotyde changes that equation completely. Clinical trials showed the pill can match top treatments like AbbVie's Skyrizi and J&J's own injectable Tremfya, giving patients the same skin-clearing benefits in a form they can swallow at breakfast.

The timing matters for the 7.5 million Americans living with psoriasis, an autoimmune condition that causes painful, scaly patches on the skin. Beyond physical discomfort, the visible symptoms often trigger anxiety, depression, and social isolation. Easier access to effective treatment could improve both bodies and mental health.

The Ripple Effect

This approval could fundamentally reshape the $10 billion psoriasis treatment market. When patients have more options they actually want to use, more people stay on treatment longer. That means fewer flare-ups, less pain, and better quality of life for people who've been suffering.

The pill format also opens doors for patients who've been sitting on the sidelines. People who work jobs where they can't easily give themselves injections, those with needle phobias, and patients in areas with limited access to specialty care now have a path forward.

Analysts project Icotyde could reach more than $5 billion in annual sales at its peak, not by stealing patients from other drugs, but by expanding the market to people who weren't being treated at all.

Johnson & Johnson expects to make the drug available within weeks. For countless people who've avoided treatment or struggled with injections, relief is finally coming in a form that fits their lives.